Table 5.
HLA testing and duodenal biopsy findings in sero-positive IBD and control
| Number of patients with positive for tTG or DGP (n) | Crohn’s disease | Ulcerative colitis | Control | Total | |
|---|---|---|---|---|---|
| (n = 15) | (n = 16) | (n = 3) | (n = 34) | ||
| HLA type (n) | DQ8 | 2 | 1 | 1 | 4 |
| DQ2 | 0 | 0 | 0 | 0 | |
| Number of sero-positive patients with duodenal biopsy (n) | Crohn’s disease | Ulcerative colitis | Control | Total |
|---|---|---|---|---|
| (n = 13) | (n = 14) | (n = 3) | (n = 30) | |
| Mild villous atrophy and increased IELs (n) | 1 | 0 | 0 | 1 |
| Increased IELs only (n) | 1 | 3 | 0 | 4 |
tTG serum tissue trans glutaminase (IgA), DGP serum deamidated gliadin peptide (IgA), EMA serum anti-endomysial antibody, HLA human leukocyte antigen, IEL intraepithelial lymphocyte